Human IL-1RAP Antibody - Nidanilimab Biosimilar

Human IgG1 - CAS #2171061-85-9

ABOUT

Anti-human IL-1R3 (IL1RAP) - Nidanilimab biosimilar - CAS #2171061-85-9

Anti-hIL1RAP-hIgG1is a biosimilar antibody of Nidanilimab, a human interleukin 1 receptor accessory protein (IL1RAP or IL1R3) antibody that blocks IL-1α and IL-1β signaling. This monoclonal antibody (mAb), also known as Nadunolimab or CAN04, is under investigation for the treatment of various solid cancer types, including pancreatic cancer and refractory non-small-cell lung cancer (NSCLC).

More detailsMore details

Anti-hIL1RAP-hIgG1 comprises the variable region of Nidanilimab and the IgG1 constant region of Nidanilimab for high effector functions.

This mAb can be used together with HEK-Blue™ IL-1β cells for screening and neutralization assays to block IL-1 signaling induced by recombinant human IL-1β (see figure). Nidanilimab also inhibits the signaling of human IL-1α, IL-33, and IL-36α (data not shown).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

All products are for internal research use only, and not for human or veterinary use.

Binding of anti-IL1RAP mAb
Binding of anti-IL1RAP mAb

SPECIFICATIONS

Specifications

Target

Human IL-1R3, IL-1RAP, IL1RAP, IL-1RAcP

Target species

Human

Species
Human
Isotype
hIgG1
kappa
Recommended isotype control
Human IgG1 Isotype Control Antibody
Clone
Nidanilimab
CAS number
2171061-85-9
Synonyms
Nadunolimab
CAN04
CANFOUR
Molecular weight
144.5 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay, ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL1RAP-hIgG1
  • Cat code: 
    hil1rap-mab1
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Nidanilimab/Nadunolimab background

Nidanilimab (CAN04, Nadunolimab) is a fully humanized monoclonal antibody (mAb) that targets interleukin-1 receptor accessory protein IL-1R3, also known as IL-1RAP or IL-1RAcP [1].

IL-1RAP is a co-receptor essential for signaling by several IL-1 family cytokines, including IL-1α, IL-1β, IL-33, and IL-36 [1]. IL-1RAP mediates signal transduction by associating with the primary ligand-binding receptors IL-1R1, ST2, or IL-1R6. This activates the transcription factorsNF-κB and AP-1, leading to the expression of pro-inflammatory genes [1].

Nidanilimab was designed to disrupt the IL-1RAP-dependent signaling pathways and to induce antibody-dependent cellular cytotoxicity (ADCC) in IL-1RAP-expressing cells. As IL-1RAP is found to be overexpressed in multiple hematological and solid cancers, it is considered a promising therapeutic target. Multiple clinical trials were launched to assess the safety, tolerability, and efficacy of Nidanilimab, both as a monotherapy and in combination with chemotherapy regimens [1-3].

 

References:

1. Fields JK, et al., 2021. Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor. Front Immunol. ;12:779100. 
2. Robbrecht D, et al., 2022. First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. Br J Cancer. 126(7):1010-1017.
2. Frenay J, et al., 2022. IL-1RAP, a Key Therapeutic Target in Cancer. Int J Mol Sci. ;23(23):14918.

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?